Comparison of Manual and Automatic Methods of Ki-67 Proliferation Index for Neuroendocrine Tumors: The Development and Validation of a Novel Digital Pathology Tool (Ki-67Counter) Abstract #813

Introduction: Ki-67 proliferation index is an increasingly important biomarker used to grade neuroendocrine tumors. Manual counting methods are laborious and subject to inter- and intra-observer variability. Digital counting methods hold promise for fast and reproducible indices, however, they are fraught with technical difficulties.
Aim(s): To develop an automated tool, Ki-67Counter, to improve the speed, reproducibility, and accuracy of automatic Ki-67 counting.
Materials and methods: We have created digital Ki-67 slides of 46 biopsy and/or resections of pancreatic and gastrointestinal neuroendocrine tumors from the University of Kentucky.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Pathology, grading, staging
Presenting Author: Dr. Lin Yang

To read results and conclusion, please login ...

Further abstracts you may be interested in

#696 Downgrading Due to Ki-67 Index Assessment with Image Analysis
Introduction: The latest WHO classification for neuroendocrine tumors (NET) defines their grade according to Ki-67 and mitotic index. These parameters have both shown to be prognostic.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD, PhD Marie-Louise Van Velthuysen
#737 Impact of Ki-67 Proliferative Index on Survival in Patients with Typical and Atypical Pulmonary Carcinoids
Introduction: Currently pulmonary carcinoids are separated into typical and atypical tumors based on mitotic count and presence of necrosis, according to the WHO classification. Whereas for GEP NETs the ENETS Guidelines have been incorporated into the WHO classification and grading is based on mitotic counts and Ki-67 index, the use of the Ki-67 index for grading pulmonary carcinoids is still under debate.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Surgical treatment
Presenting Author: Dr Martina Rudelius
#791 Quantification of Somatostatin Receptor Subtypes Using In Vivo PET/CT-Data, Ex Vivo Conventional Immunohistochemistry and Automated Digitized Analysis by Definiens XD Image Software
Introduction: Diagnostics and therapy of NET are significantly influenced by their somatostatin receptor (SSTR) status. Immunohistochemistry (IHC) of SSTR performed by pathologists is a time-consuming and cost-intensive procedure.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Pathology, grading, staging
Presenting Author: Dr. med. Daniel Kaemmerer
Keywords: SSTR
#2951 Analysis of Discordance between Biopsy Grade and Surgical Pathology Grade in Resected PanNEN Patients
Introduction: In PanNEN cases, treatment strategies are decided by tumor localization, volume and grade. In unresectable or metastatic cases, tumor grade is determined by biopsy specimen obtained from EUS-FNA and diagnostic accuracy of biopsy according to WHO classification 2017 is important for decision making of treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: Kenzo Nakano
Authors: Nakano K, Masui T, Yogo A, Uchida Y, ...
#126 Assessment of the proliferation marker Ki-67 by endoscopic ultrasound guided-Fine Needle Aspiration (EUS-FNA) in pancreatic endocrine tumors: A comparative analysis with histology of the surgical specimen
Introduction: Assessment of the proliferative index by Ki-67 immuno-labelling is an important prognostic parameter for the biologic behavior of digestive neuroendocrine tumors, usually established on the histological specimen obtained after surgery or macro-biopsy. However, small pancreatic endocrine tumors (PET) are more and more often recognized by CT/MRI and diagnosed by EUS. The value of Ki-67 labelling index (Ki-67-LI) on fine needle aspiration (FNA) is not well-established in this setting, although regularly assessed.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Ivan Borbath